Logo image of KOD

KODIAK SCIENCES INC (KOD) Stock Fundamental Analysis

NASDAQ:KOD - Nasdaq - US50015M1099 - Common Stock - Currency: USD

4.45  -0.29 (-6.12%)

After market: 4.45 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KOD. KOD was compared to 571 industry peers in the Biotechnology industry. While KOD seems to be doing ok healthwise, there are quite some concerns on its profitability. KOD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KOD had negative earnings in the past year.
In the past year KOD has reported a negative cash flow from operations.
KOD had negative earnings in each of the past 5 years.
KOD had a negative operating cash flow in each of the past 5 years.
KOD Yearly Net Income VS EBIT VS OCF VS FCFKOD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

KOD has a Return On Assets (-51.42%) which is comparable to the rest of the industry.
With a Return On Equity value of -103.37%, KOD perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
ROA -51.42%
ROE -103.37%
ROIC N/A
ROA(3y)-44.65%
ROA(5y)-31.92%
ROE(3y)-71.6%
ROE(5y)-48.79%
ROIC(3y)N/A
ROIC(5y)N/A
KOD Yearly ROA, ROE, ROICKOD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

KOD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KOD Yearly Profit, Operating, Gross MarginsKOD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, KOD has more shares outstanding
Compared to 5 years ago, KOD has more shares outstanding
KOD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KOD Yearly Shares OutstandingKOD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
KOD Yearly Total Debt VS Total AssetsKOD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -5.31, we must say that KOD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.31, KOD is doing worse than 63.99% of the companies in the same industry.
There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.31
ROIC/WACCN/A
WACCN/A
KOD Yearly LT Debt VS Equity VS FCFKOD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 8.42 indicates that KOD has no problem at all paying its short term obligations.
KOD has a Current ratio of 8.42. This is in the better half of the industry: KOD outperforms 73.80% of its industry peers.
KOD has a Quick Ratio of 8.42. This indicates that KOD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of KOD (8.42) is better than 73.97% of its industry peers.
Industry RankSector Rank
Current Ratio 8.42
Quick Ratio 8.42
KOD Yearly Current Assets VS Current LiabilitesKOD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.54% over the past year.
EPS 1Y (TTM)29.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KOD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.63% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.39%
EPS Next 2Y10.78%
EPS Next 3Y9.72%
EPS Next 5Y7.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KOD Yearly Revenue VS EstimatesKOD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
KOD Yearly EPS VS EstimatesKOD Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KOD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KOD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KOD Price Earnings VS Forward Price EarningsKOD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KOD Per share dataKOD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.78%
EPS Next 3Y9.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KOD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KODIAK SCIENCES INC

NASDAQ:KOD (2/21/2025, 8:00:02 PM)

After market: 4.45 0 (0%)

4.45

-0.29 (-6.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners80.49%
Inst Owner Change-96.32%
Ins Owners5.66%
Ins Owner Change0%
Market Cap234.16M
Analysts51.43
Price Target7.14 (60.45%)
Short Float %4.1%
Short Ratio4.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.19%
Min EPS beat(2)2.4%
Max EPS beat(2)7.98%
EPS beat(4)3
Avg EPS beat(4)-2.57%
Min EPS beat(4)-44.67%
Max EPS beat(4)24%
EPS beat(8)5
Avg EPS beat(8)-1.17%
EPS beat(12)7
Avg EPS beat(12)-3.15%
EPS beat(16)8
Avg EPS beat(16)-4.41%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)66.67%
EPS NQ rev (1m)-0.12%
EPS NQ rev (3m)-0.12%
EPS NY rev (1m)0%
EPS NY rev (3m)2.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-3.65
EYN/A
EPS(NY)-3.83
Fwd EYN/A
FCF(TTM)-2.8
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0
BVpS3.52
TBVpS3.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.42%
ROE -103.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.65%
ROA(5y)-31.92%
ROE(3y)-71.6%
ROE(5y)-48.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 147.58%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.42
Quick Ratio 8.42
Altman-Z -5.31
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2600.91%
Cap/Depr(5y)1868.51%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.58%
EPS Next Y30.39%
EPS Next 2Y10.78%
EPS Next 3Y9.72%
EPS Next 5Y7.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.48%
EBIT Next 3Y1.29%
EBIT Next 5YN/A
FCF growth 1Y44.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.21%
OCF growth 3YN/A
OCF growth 5YN/A